School of Life Sciences, Jiangsu University, Zhenjiang, China.
The Laboratory Animal Research Center, Jiangsu University, Zhenjiang, China.
Cancer Biother Radiopharm. 2022 Jun;37(5):335-341. doi: 10.1089/cbr.2020.4630. Epub 2021 Mar 18.
Chimeric antigen receptor T cell therapy (CART) has achieved excellent results in the past 10 years for treating of leukemia. Treatment of B cell acute lymphoblastic leukemia by anti-CD19 CART can reach a complete remission rate of 90%. Although CART has greatly improved the treatment of patients with leukemia and lymphoma, as many as one-third of the patients can suffer disease relapse after CART. The tumor surface marker CD19 is negative in most the patients who relapse, and these patients display high expression of CD19 before treatment. In this review, the current causes of CD19-negative relapses after CD19 CART against leukemia, and the mechanisms of target escape are briefly summarized. Also, methods and strategies for treating relapse to provide references for the treatment of leukemia relapse are also discussed.
嵌合抗原受体 T 细胞疗法（CART）在过去 10 年中治疗白血病取得了优异的效果。抗 CD19 CART 治疗 B 细胞急性淋巴细胞白血病的完全缓解率可达 90%。尽管 CART 极大地改善了白血病和淋巴瘤患者的治疗效果，但多达三分之一的患者在 CART 后可发生疾病复发。大多数复发患者的肿瘤表面标志物 CD19 呈阴性，且这些患者在治疗前高表达 CD19。本综述简要总结了抗 CD19 CART 治疗白血病后 CD19 阴性复发的当前原因及靶标逃逸的机制，并探讨了针对复发的治疗方法和策略，为白血病复发的治疗提供参考。
